7 / 78
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 6, November/December 2017
AFRICA
345
References
1.
Singer DE, Albers GW, Dalen, JE, Fang MC, Go AS, Halperin, JL,
et
al
. Antithrombotic therapy in atrial fibrillation. American College of
Chest Physicians.
Chest
2008;
133
(6): 546S–592S. Available at: http://
www.ncbi.nlm.nih.gov/pubmed/18574273 (Accessed Nov 11th 2017).
2.
Hylek EM. Vitamin K antagonists and time in the therapeutic range:
implications, challenges, and strategies for improvement.
J Thromb
Thrombol
2013;
35
(3): 333–335. Available from:
http://www.ncbi.nlm.
nih.gov/pubmed/23456572 (Accessed Nov 11th 2017).
3.
Hart RG, Pearce L.A, Aguilar MI. Meta-analysis: antithrombotic
therapy to prevent stroke in patients who have nonvalvular atrial fibril-
lation.
Ann Int Med
2007;
146
: 857–867.
4.
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti
G. Oral anticoagulant therapy: Antithrombotic therapy and prevention
of thrombosis. 9th edn. American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines.
Chest
2012;
141
(2 Suppl): e44S–88S.
Available at:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3278051&tool=pmcentrez&rendertype=abstract (Accessed November
11
th
2017).
5.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ,
et
al
. Adverse drug reactions as cause of admission to hospital: prospective
analysis of 18 820 patients.
Br Med J
2004:
329
: 15–19.
6.
Yousef ZR, Tandy SC, Tudor V, Jishi F, Trent RJ, Watson DK,
et al
.
Warfarin for non-rheumatic atrial fibrillation: five-year experience in a
district general hospital.
Heart
2004; 90: 1259–1262.
7.
Johnson CE, LimWK, Workman BS. People aged over 75 in atrial fibril-
lation on warfarin: the rate of major hemorrhage and stroke in more
than 500 patient-years of follow-up.
J Am Geriatr Soc
2005;
53
: 655–659.
8.
Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet
therapy for preventing stroke in patients with non-valvular atrial fibril-
lation and no history of stroke or transient ischemic attacks
. Cochrane
Database Syst Rev
2007;
3
: 1–34. Available from:
http://doi.wiley.
com/10.1002/14651858.CD006186.pub2. (Accessed 11 Nov 2017).
9.
Mouton JP, Njuguna C, Kramer N, Stewart A, Mehta U, Blockman
M,
et al.
Adverse drug reactions causing admission to medical wards.
Medicine
(Baltimore) 2016;
95
(19): 1–10.
10. Mouton JP, Mehta U, Parrish AG, Wilson DP, Stewart A, Njuguna CW,
et al
. Mortality from adverse drug reactions in adult medical inpatients
at four hospitals in South Africa: a cross-sectional survey.
Br J Clin
Pharmacol
2015;
80
(4): 818–826.
11. Van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect
of study setting on anticoagulation control: a systematic review and
metaregression. Chest 2006:
129
(5): 1155–1166. Available at: http://
www.ncbi.nlm.nih.gov/pubmed/16685005. (Accessed 12 Nov 2017).
12. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs
MJ,
et al
. Evidence-based management of anticoagulant therapy:
Antithrombotic Therapy and Prevention of Thrombosis. 9th edn.
American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines.
Chest
2012:
141
(2 Suppl): e152S–184S.Available at: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3278055&tool=p
mcentrez&rendertype=abstract (Accessed 11 Nov 2017).
13. Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene
variants associated with warfarin dosage variability in the South African
black population.
Pharmacogenomics
2011:
2
(7): 953–963.
14. Van Spall HGC Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R,
Yang S,
et al
. Variation in warfarin dose adjustment practice is respon-
sible for differences in the quality of anticoagulation control between
centers and countries: an analysis of patients receiving warfarin in the
randomized evaluation of long-term anticoagulation the.
Circulation
2012:
126
(19): 2309–2316. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23027801 (Accessed 11 Nov 2017).
15. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi
MG,
et al.
Efficacy and safety of dabigatran compared with warfarin
at different levels of international normalised ratio control for stroke
prevention in atrial fibrillation: an analysis of the RE-LY trial.
Lancet
2010:
376
(9745): 975–983. Available at:
http://dx.doi.org/10.1016/S0140-6736(10)61194-4.
16. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P,
et
al
. Anticoagulation control and prediction of adverse events in patients
with atrial fibrillation. A systematic review.
Circ Cardiovasc Qual
Outcomes
2008;
1
: 84–91. (Accessed 11 Nov 2017).
17. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi
MG,
et al
; ACTIVE W Investigators. Benefit of oral anticoagulant
over antiplatelet therapy in atrial fibrillation depends on the quality of
international normalized ratio control achieved by centers and coun-
tries as measured by time in therapeutic range.
Circulation
2008;
118
:
2029–2037. (Accessed 11 Nov 2017).
18. Singer DE, Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW,
Lokhnygina Y,
et al
. Impact of global geographic region on time
in therapeutic range on warfarin anticoagulant therapy: data from
the ROCKET AF clinical trial.
J Am Heart Assoc
2013; 1: e000067.
Available at:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3603243&tool=pmcentrez&rendertype=abstract (Accessed 11 Nov
2017).
19. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess
the quality of warfarin control in atrial fibrillation patients in the United
States.
J Managed Care Pharm
2009;
15
(3): 244–152. Available at: http://
www.ncbi.nlm.nih.gov/pubmed/19326955. (Accessed 12 Nov 2017).